Evidence map›Paper›PMID 41088024›Full record

ArticleBMC pulmonary medicine2025

Prognostic impact of muscle mass in idiopathic interstitial pneumonia: analysis of idiopathic pulmonary fibrosis and other idiopathic interstitial pneumonias.

Hirotaka Hagiwara, Tomotsugu Takano, Hiroaki Ogata, Kazuya Tsubouchi, Katsuyuki Ichiki, Shohei Takata, Hiroshi Ishii, Yasuhiko Kitasato, Yoshiaki Zaizen, Kazuhiro Yatera and 15 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Hirotaka HagiwaraDepartment of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Tomotsugu TakanoDepartment of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. tomotsugutakano@gmail.com.
Hiroaki OgataDepartment of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Kazuya TsubouchiDepartment of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Katsuyuki IchikiKirigaoka Tsuda Hospital, Kitakyushu, Japan.
Shohei TakataDepartment of Respiratory Diseases, NHO Fukuoka Higashi Medical Center, Fukuoka, Japan.
Hiroshi IshiiDepartment of Respiratory Medicine, Fukuoka University Chikushi Hospital, Chikushino, Japan.
Yasuhiko KitasatoDepartment of Respiratory Medicine, Japan Community Health Care Organization Kurume General Hospital, Kurume, Japan.
Yoshiaki ZaizenDivision of Respirology, Neurology, and Rheumatology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.
Kazuhiro YateraDepartment of Respiratory Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Masayuki KawasakiDepartment of Respiratory Diseases, NHO Omuta National Hospital, Omuta, Japan.
Masaki FujitaDepartment of Respiratory Medicine, Fukuoka University School of Medicine, Fukuoka, Japan.
Makoto YoshidaDepartment of Respiratory Diseases, NHO Fukuoka National Hospital, Fukuoka, Japan.
Takashige MaeyamaDepartment of Respiratory Medicine, Hamanomachi Hospital, Fukuoka, Japan.
Ayano MashimotoDepartment of Respiratory Medicine, Japan Community Health Care Organization Kyushu Hospital, Kitakyushu, Japan.
Kazuto FuruyamaDepartment of Respiratory Medicine, Saiseikai Fukuoka General Hospital, Fukuoka, Japan.
Ryo ToriiDepartment of Respiratory Medicine, Wakamatsu Hospital of the University of Occupational and Environmental Health, Kitakyushu, Japan.
Kunihiro SuzukiDepartment of Respiratory Medicine, Steel Memorial Yawata Hospital, Kitakyushu, Japan.
Yuichi MizutaDepartment of Respiratory Medicine, St. Mary's Hospital, Kurume, Japan.
Kazunori TobinoDivision of Respiratory Medicine, Aso Iizuka Hospital, Iizuka, Japan.
Eiji HaradaDepartment of Respiratory Medicine, Kitakyushu Municipal Medical Center, Kitakyushu, Japan.
Fumiaki KiyomiClinical Research Support Center Kyushu, Fukuoka, Japan.
Hidetake YabuuchiDepartment of Health Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Yoichi NakanishiKitakyushu City Hospital Organization, Kitakyushu, Japan.
Isamu OkamotoDepartment of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLow skeletal muscle mass has been reported to associated with poor prognosis in patients with idiopathic pulmonary fibrosis (IPF). However, such associations have scarcely reported in idiopathic interstitial pneumonias (IIPs) other than IPF. Quantification of muscle mass obtained from chest computed tomography (CT) is used as a simple screening tool for sarcopenia in patients with respiratory diseases. However, the optimal thoracic site for muscle mass quantification is controversial. Moreover, there have been no reports investigating the association between muscle mass and acute exacerbations. This study aimed to evaluate optimal site for muscle mass quantification in chest CT to predict survival and acute exacerbation in IPF and non-IPF idiopathic interstitial pneumonias.

methodsThis study included 528 patients diagnosed with IIP at 29 facilities between September 1, 2013, and April 30, 2016, following multidisciplinary discussions with prospective follow-up over a 5-year period. The cohort was divided into two groups: those with IPF and those with non-IPF IIPs. Skeletal muscle mass was quantified using the erector spinae muscle index (ESMI) and pectoralis muscle index (PMI), defined as the respective muscle area on chest computed tomography (CT) divided by height squared at the time of enrollment. Associations between these indices at baseline and both survival and acute exacerbation were analyzed.

resultsIn both IPF and non-IPF cohorts, Cox regression analysis revealed that patients with low ESMI had a poorer prognosis compared to those with normal ESMI, even after adjusting for age, sex, % forced vital capacity (FVC), and smoking exposure level. The hazard ratios were 0.62 (95% CI 0.40–0.90; p = 0.013) and 0.46 (95% CI 0.26–0.83; p = 0.009), respectively. In contrast, no significant relationship was identified between PMI and survival. Multivariable Cox regression analysis confirmed that ESMI was an independent predictor of survival in both IPF and non-IPF patients. Additionally, acute exacerbations occurred more frequently in the low ESMI group and low PMI group, particularly among non-IPF patients.

conclusionsThe ESMI obtained from chest CT is associated with survival in not only in IPF patients but also in the non-IPF patients. The ESMI and PMI also associate with acute exacerbations in non-IPF patients.

Indexed as

Idiopathic Interstitial PneumoniasIdiopathic Pulmonary FibrosisMuscle, SkeletalPectoralis MusclesSarcopeniaAgedDisease ProgressionFemaleHumansMaleMiddle AgedPrognosisProportional Hazards ModelsProspective StudiesTomography, X-Ray Computed5-year survival rateAcute exacerbationIdiopathic interstitial pneumoniaMuscle massReal-world registry

Identifiers

PMID41088024
PMCPMC12522827

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.